The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The multiple myeloma market has been comprehensively analyzed in IMARC’s new report titled “Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”. Multiple myeloma is a cancer of the plasma cells. Plasma cells are white blood cells that make antibodies which protect against infection. Multiple myeloma involves an excessive growth of the cells crowding out normal cells in the bone marrow that produce red blood cells, platelets, and other white blood cells. Early on, patients having multiple myeloma might not notice any symptoms. But over time, they may develop common symptoms which include bone pain, weakness and fatigue, weight loss and loss of appetite, stomach problems, confusion, frequent infections, severe thirst, weakness or numbness in arms and legs, etc. Multiple myeloma can be hard to diagnose as it usually has few or no symptoms in the initial stages. Diagnosis for multiple myeloma may involve a range of blood tests, urine tests and bone or bone marrow tests. A number of these tests may also be used to assess the extent of the disease and to plan and monitor treatment.
One of the biggest drivers of the multiple myeloma market is the rising geriatric population. Since the incidence of multiple myeloma increases with age and rarely happens in people younger than 45 years of age, we expect a continuous growth in the global ageing population to create a positive impact on the multiple myeloma market. Furthermore, a rising prevalence of physical inactivity, overweight, obesity, and diabetes are also expected to drive this market as these factors are also associated with an increasing incidence and mortality of this indication. Multiple myeloma is now treated like a chronic disorder catalyzed by the rising efficiency and safety of currently available treatments. The cost of therapy for multiple myeloma, however, has become increasingly high as patients are living longer and use these treatments for extended periods of time. This cost burden on both payers and providers, however, will get some relief once generic versions for some of the key drugs are launched across the major markets.
IMARC Group’s new report provides an exhaustive analysis of the multiple myeloma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple myeloma market in any manner
Time Period of the Study
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current multiple myeloma marketed drugs and late-stage pipeline drugs.
Late-Stage Pipeline Drugs
Key Questions Answered in this Report
Multiple Myeloma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at